GCG and type 2 diabetes mellitus: GLP‐1 agonist treatment improves glycaemia, aids weight loss, improves cardiovascular, renal and limb outcomes, and leads to a reduction in all‐cause mortality in type 2 diabetes (Kristensen et al., 2019; Zheng et al., 2018).